Registry of Patients With Hematologic Disease and COVID-19 in Russia
NCT ID: NCT04422470
Last Updated: 2023-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
666 participants
OBSERVATIONAL
2020-06-22
2022-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
NCT04416438
Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19
NCT04391946
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
NCT02885766
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
NCT01254890
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
NCT04452604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-interventional study
Non-interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any previously or currently diagnosed hematologic disease
* Laboratory confirmed or suspected (based on clinical symptoms and/or CT) COVID-19
* Known outcome of COVID-19 in case of retrospective data input (protocol allows retrospective data input for patients who were prospectively followed in local centers)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Foundation for Cancer Research Support (RakFond)
UNKNOWN
Enrollme.ru, LLC
NETWORK
National Research Center for Hematology, Russia
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elena Parovichnikova
Role: STUDY_CHAIR
National Research Center for Hematology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Republican Clinical Hospital of Tatarstan
Kazan', , Russia
City Hospital n.a. V.V. Veresaev
Moscow, , Russia
Clinical Hospital n.a. S.P. Botkin
Moscow, , Russia
N.V. Sklifosovsky Emergency Institute
Moscow, , Russia
National Research Center for Hematology
Moscow, , Russia
Regional Clinical Hospital N.A. Semashko
Nizhny Novgorod, , Russia
Regional Hospital
Novosibirsk, , Russia
Regional Clinical Hospital
Omsk, , Russia
RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University
Saint Petersburg, , Russia
Republican Clinical Hospital No4
Saransk, , Russia
Republic Clinical Hospital n.a. N.A. Semashko
Ulan-Ude, , Russia
Regional Clinical Hospital
Vladimir, , Russia
Regional Clinical Hospital No2
Vladivostok, , Russia
Regional Clinical Hospital
Yaroslavl, , Russia
Regional Clinical Hospital No1
Yekaterinburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRONOS19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.